



## Alzinova advanced partner discussions at the J.P. Morgan Healthcare Conference in San Francisco

Alzinova AB (publ) (Nasdaq First North: ALZ) participated in the J.P. Morgan Healthcare Conference held in San Francisco between January 12–15, 2026. During the week, Alzinova's management actively advanced ongoing discussions with potential partners and investors, with a clear focus on the continued development of the vaccine candidate ALZ-101.

The J.P. Morgan Healthcare Conference represents a key arena for strategic dialogue within the global pharmaceutical industry. For Alzinova, the conference serves as an important forum to build on existing interactions, present recent clinical and regulatory progress, and further clarify the company's development strategy ahead of the next clinical phase.

### **Tord Labuda, CEO of Alzinova, comments:**

*"J.P. Morgan is an important forum for progressing strategic dialogues with partners and investors. For Alzinova, the conference provided a valuable opportunity to advance discussions around ALZ-101 and to clarify how we plan to develop the program in the next clinical phase."*

During the meetings, Alzinova highlighted its positive Phase 1b data, the regulatory positioning of ALZ-101, including FDA Fast Track designation, and the preparatory work underway to support the next stage of clinical development.

### **About the J.P. Morgan Healthcare Conference**

The annual J.P. Morgan Healthcare Conference is the world's largest healthcare investment symposium, bringing together global pharmaceutical companies, emerging biotech firms and life science investors. The conference serves as a key platform for strategic dialogue, business development and capital markets engagement.

### **For further information, please contact:**

Tord Labuda, CEO  
E-mail: [info@alzinova.com](mailto:info@alzinova.com)

### **About Alzinova AB**

Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented A $\beta$ CC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 55 million



affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

**Attachments**

**Alzinova advanced partner discussions at the J.P. Morgan Healthcare Conference in San Francisco**